Stroke and its consequences: protocol and pilot data of the observational Berlin Long-term Observation of Vascular Events (BeLOVE) stroke stratum.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nolte Christian H, Weber Joachim E, Ahmadi Michael, Boldt Leif-Hendrik, Braemswig Tim B, Damm Frederik, Doerrfuss Jakob I, Eckardt Kai-Uwe, Edelmann Frank, Galinovic Ivana, Gerhardt Holger, Grittner Ulrike, Hübner Norbert, Heege Jil, Kufner Anna, Liman Thomas, Meisel Andreas, Müller Dominik N, Otte Christian, Pinto Rafaela M, Piper Sophie, Rattan Simrit, von Rennenberg Regina I, Rohrpasser-Napierkowski Ira, Scheitz Jan F, Schoenrath Katharina, Schulz-Menger Jeanette, Schweizerhof Oliver, Sperber Pia S, Steindorf-Sabath Lena, Stegemann Alina, Stengl Helena, Villringer Kersten, Landmesser Ulf, Mai Knut, Pischon Tobias, Endres Matthias
Аннотация
METHODS AND ANALYSIS: BeLOVE is a prospective, longitudinal, observational, hospital-based cohort study. Its stroke stratum enrols adult patients with acute ischaemic stroke, transient ischaemic attack (TIA) or non-traumatic intracerebral haemorrhage. Patients undergo deep phenotyping including cerebral and cardiac MRI, ECG, echocardiography and bio-sampling including multi-omics analyses. Regular, standardised follow-ups take place annually over a period of up to 10 years and record the frequency of MACE as the primary outcome.Secondary outcomes include the frequency, progression and interactions of functional impairments, namely post-stroke cognition, pain, depression, seizures and their relationship to quality of life.The first study phase included 758 patients (median 69 years, 37% female). At 2-year follow-up, the cumulative incidence (95% CI) of the composite primary endpoint MACE was 0.107 (0.085 to 0.132) and that of first ischaemic stroke, first myocardial infarction and death were 0.066 (0.049 to 0.086), 0.015 (0.008 to 0.026) and 0.040 (0.027 to 0.056), respectively.
ETHICS AND DISSEMINATION: Each participant will provide informed written consent during the acute in-hospital phase. Data will be available for research purposes via a written request to the data use and access committee.
TRIAL REGISTRATION NUMBER: German Clinical Trials Register: http://www.drks.de/DRKS00023323 on 4 November 2020.